The White House
Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will sell medicines at a discounted price on TrumpRx.
The executive order says it revokes attempts to paralyze the AI industry and establishes an AI Litigation Task Force to challenge state AI laws inconsistent with national policy.
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.
The Conference Board's principal economic policy analyst PJ Tabit says that while the plan is helpful, it is not a comprehensive framework for how to regulate AI.